Literature DB >> 18663007

Pseudomonas aeruginosa induces localized immunosuppression during pneumonia.

Maureen H Diaz1, Ciara M Shaver, John D King, Srinidhi Musunuri, Jeffrey A Kazzaz, Alan R Hauser.   

Abstract

Hospital-acquired bacterial pneumonia is a common and serious complication of modern medical care. Many aspects of such infections remain unclear, including the mechanisms by which invading pathogens resist clearance by the innate immune response and the tendency of the infections to be polymicrobial. Here, we used a mouse model of infection to show that Pseudomonas aeruginosa, a leading cause of hospital-acquired pneumonia, interferes with the ability of recruited phagocytic cells to eradicate bacteria from the lung. Early in infection, phagocytic cells, predominantly neutrophils, are recruited to the lungs but are incapacitated when they enter the airways by the P. aeruginosa toxin ExoU. The resulting paucity of functioning phagocytes allows P. aeruginosa to persist within the lungs and results in local immunosuppression that facilitates superinfection with less-pathogenic bacteria. Together, our results provide explanations for previous reports linking ExoU-secreting P. aeruginosa with more severe pulmonary infections and for the tendency of hospital-acquired pneumonia to be polymicrobial.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18663007      PMCID: PMC2546837          DOI: 10.1128/IAI.00012-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  56 in total

1.  Biological effects of Pseudomonas aeruginosa type III-secreted proteins on CHO cells.

Authors:  A J Vallis; V Finck-Barbançon; T L Yahr; D W Frank
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. II. Effects of lecithinase and protease.

Authors:  P V Liu
Journal:  J Infect Dis       Date:  1966-02       Impact factor: 5.226

3.  Incidence and outcome of polymicrobial ventilator-associated pneumonia.

Authors:  Alain Combes; Corinne Figliolini; Jean-Louis Trouillet; Najibi Kassis; Michel Wolff; Claude Gibert; Jean Chastre
Journal:  Chest       Date:  2002-05       Impact factor: 9.410

Review 4.  ExoU is a potent intracellular phospholipase.

Authors:  Hiromi Sato; Dara W Frank
Journal:  Mol Microbiol       Date:  2004-09       Impact factor: 3.501

5.  Isolation and characterization of transposon-induced mutants of Pseudomonas aeruginosa deficient in production of exoenzyme S.

Authors:  T I Nicas; B H Iglewski
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

6.  In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors.

Authors:  Rebecca M Phillips; David A Six; Edward A Dennis; Partho Ghosh
Journal:  J Biol Chem       Date:  2003-08-12       Impact factor: 5.157

7.  Effector ExoU from the type III secretion system is an important modulator of gene expression in lung epithelial cells in response to Pseudomonas aeruginosa infection.

Authors:  B McMorran; L Town; E Costelloe; J Palmer; J Engel; D Hume; B Wainwright
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

8.  Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia.

Authors:  Grant S Schulert; Heather Feltman; Shira D P Rabin; Ciara G Martin; Scott E Battle; Jordi Rello; Alan R Hauser
Journal:  J Infect Dis       Date:  2003-11-21       Impact factor: 5.226

9.  The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU.

Authors:  Hiromi Sato; Dara W Frank; Cecilia J Hillard; Jimmy B Feix; Ravi R Pankhaniya; Kiyoshi Moriyama; Viviane Finck-Barbançon; Adam Buchaklian; Ming Lei; Roy M Long; Jeanine Wiener-Kronish; Teiji Sawa
Journal:  EMBO J       Date:  2003-06-16       Impact factor: 11.598

Review 10.  Lung infections associated with cystic fibrosis.

Authors:  Jeffrey B Lyczak; Carolyn L Cannon; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

View more
  52 in total

1.  Role of the membrane localization domain of the Pseudomonas aeruginosa effector protein ExoU in cytotoxicity.

Authors:  Jeff L Veesenmeyer; Heather Howell; Andrei S Halavaty; Sebastian Ahrens; Wayne F Anderson; Alan R Hauser
Journal:  Infect Immun       Date:  2010-05-17       Impact factor: 3.441

Review 2.  Innate immune responses to Pseudomonas aeruginosa infection.

Authors:  Elise G Lavoie; Tamding Wangdi; Barbara I Kazmierczak
Journal:  Microbes Infect       Date:  2011-08-02       Impact factor: 2.700

Review 3.  Innate Immune Signaling Activated by MDR Bacteria in the Airway.

Authors:  Dane Parker; Danielle Ahn; Taylor Cohen; Alice Prince
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

4.  Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion.

Authors:  Daniel Aiello; John D Williams; Helena Majgier-Baranowska; Ishan Patel; Norton P Peet; Jin Huang; Stephen Lory; Terry L Bowlin; Donald T Moir
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

5.  Activation of ExoU phospholipase activity requires specific C-terminal regions.

Authors:  Katherine M Schmalzer; Marc A Benson; Dara W Frank
Journal:  J Bacteriol       Date:  2010-01-22       Impact factor: 3.490

6.  Insulin treatment modulates the host immune system to enhance Pseudomonas aeruginosa wound biofilms.

Authors:  Chase Watters; Jake A Everett; Cecily Haley; Allie Clinton; Kendra P Rumbaugh
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

7.  Pathogenicity islands PAPI-1 and PAPI-2 contribute individually and synergistically to the virulence of Pseudomonas aeruginosa strain PA14.

Authors:  Ewan M Harrison; Melissa E K Carter; Shelley Luck; Hong-Yu Ou; Xinyi He; Zixin Deng; Chris O'Callaghan; Aras Kadioglu; Kumar Rajakumar
Journal:  Infect Immun       Date:  2010-02-01       Impact factor: 3.441

8.  Pseudomonas aeruginosa Effector ExoS Inhibits ROS Production in Human Neutrophils.

Authors:  Chairut Vareechon; Stephanie Elizabeth Zmina; Mausita Karmakar; Eric Pearlman; Arne Rietsch
Journal:  Cell Host Microbe       Date:  2017-05-10       Impact factor: 21.023

Review 9.  Inflammation: A Double-Edged Sword in the Response to Pseudomonas aeruginosa Infection.

Authors:  Christina K Lin; Barbara I Kazmierczak
Journal:  J Innate Immun       Date:  2017-02-22       Impact factor: 7.349

10.  The hemolytic and cytolytic activities of Serratia marcescens phospholipase A (PhlA) depend on lysophospholipid production by PhlA.

Authors:  Ken Shimuta; Makoto Ohnishi; Sunao Iyoda; Naomasa Gotoh; Nobuo Koizumi; Haruo Watanabe
Journal:  BMC Microbiol       Date:  2009-12-16       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.